Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
Yishai Ofran(Shaare Zedek Medical Center), Avraham Frisch(Rambam Health Care Campus), Ofrat Beyar‐Katz(Rambam Health Care Campus), Tsila Zuckerman(Johannes Gutenberg University Mainz), Michal Hayun(Rambam Health Care Campus), Israel Henig(Rush University Medical Center), Shimrit Ringelstein‐Harlev(Rambam Health Care Campus), Dana Yehudai‐Ofir(Rambam Health Care Campus), Ilana Slouzkey(University of Haifa)
Cited by 69
Related Papers
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170
Enhancement of Human Monocyte and Peritoneal Macrophage Chemiluminescence Activities in Women With Endometriosis
|American Journal Of Reproductive Immunology|1987|165
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164